Recent studies have suggested that genetic polymorphisms in drug-metabolizing enzymes, particularly cytochrome P450 isoforms such as CYP2D6 and CYP2C19, may significantly influence individual susceptibility to SSRI-induced adverse effects, including pancreatitis (8, 14). This evidence concerns the gene CYP2C19 and pancreatitis.